Navigation Links
Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients
Date:9/22/2009

BERLIN, Sept. 22 /PRNewswire/ -- Bayer today announced results from a Phase II trial of regorafenib (BAY 73-4506), a potent oral multi-kinase inhibitor, which demonstrated that treatment with regorafenib resulted in a 31 percent partial response rate and 50 percent stabilization rate in patients with metastatic renal cell carcinoma (RCC). These data were presented in an oral session at the joint 15th Congress of the European CanCer Organisation and 34th Congress of the European Society for Medical Oncology (ECCO 15 - 34th ESMO). Preliminary results from this study were presented earlier this year at the 45th American Society of Clinical Oncology (ASCO) Annual Congress, May 29 - June 2, 2009, Orlando, Florida.

"Bayer is committed to researching and developing potential anti-cancer agents like regorafenib, which may eventually help physicians and patients manage this devastating disease," said Kemal Malik, MD, Member of the Board of Management of Bayer Schering Pharma AG and Head of Global Development. "We look forward to continuing the comprehensive clinical development program for regorafenib, which we believe could potentially represent a promising new treatment option for various tumor types."

At the time of data analysis, 81 percent of patients (n=48) in the trial experienced disease stabilization or regression. Specifically, 31 percent of patients (n=15) experienced a confirmed partial response (PR), according to the Response Evaluation Criteria in Solid Tumors (RECIST), and 50 percent of patients (n=24) experienced stable disease (SD). The data also showed an estimated median progression-free survival of 8.3 months at the time of protocol-defined end of study. Importantly, the time of data analyses, which occurred on May 31, 2009, was prospectively defined in the protocol as when the last patient was treated for at least six months. At the time of analysi
'/>"/>

SOURCE Bayer HealthCare
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014  InnoPharma, Inc. today announced the first ... equivalent of Zyprexa® injection), in Canada.  Olanzapine is indicated ... in patients with schizophrenia or bipolar I mania. ... InnoPharma has entered into an agreement with Sandoz Canada ... make, use, sell, market and distribute Olanzapine Injection in ...
(Date:7/30/2014)... and PARIS , July 30, ... ) and Sanofi (EURONEXT: SAN and NYSE: ... ODYSSEY trials of alirocumab in people with hypercholesterolemia met ... from baseline in low-density lipoprotein cholesterol (LDL-C) at 24 ... an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin ...
(Date:7/30/2014)... and NEW YORK , July ... a developer of new products for oncology supportive care, ... ® , has been featured in an article on ... Symptoms in Head and Neck Cancers."  Dr. Steve ... insight on the growing demand seen in the oncology ...
Breaking Medicine Technology:InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3
... Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo Executive Vice President and ... Sachs Global Healthcare Conference on Tuesday, June 15 , at ... Los Angeles .  The presentation will be webcast on the following ... , ...
... Epocal, Inc., a leading edge provider of point ... Food and Drug Administration (FDA) clearance to market its new ... from the epoc System are used to evaluate acid-base status ... acidity of the blood).  The addition of lactate to the ...
Cached Medicine Technology:Epocal Announces FDA Clearance of Lactate Test 2
(Date:7/30/2014)... The Restore My Blood Sugar review recently published ... levels can now find an amazingly successful method of reducing ... created by D. Chao and Andrew Forester who claim that ... it comes to normalizing blood sugar levels. Chao actually is ... to the cure of diabetes that all patients should find ...
(Date:7/30/2014)... July 30, 2014 New changes are in ... plans to move to a new facility. The official date ... will be moving soon. , MedX Pharmacy will be moving ... Pearland, TX 77581. This is the old Wells Fargo building. ... and will include a drive thru for convenient drop-off and ...
(Date:7/30/2014)... Conducting Advanced Root Cause Analysis ... and Innovative Techniques to Improve the Quality of ... Sept. 17-18, 2014 – Raleigh, NC, http://www.fdanews.com/CAPAWorkshopRaleigh ... for 483 observations since 1997. , The FDA's ... CAPA program has never been more important. , ...
(Date:7/30/2014)... drug to treat malaria, is now widespread throughout ... ( P. falciparum ) parasites that cause the ... mutation in the parasites. However, a six-day course ... three-day coursehas proved highly effective in treating drug-resistant ... the New England Journal of Medicine . ...
(Date:7/30/2014)... July 30, 2014 (HealthDay News) -- It can happen in ... television, dresser or computer monitor and gets critically injured when ... a young child should look around their homes and imagine ... child. Imagining it is better than it becoming a reality," ... Physicians, said in a college news release. Between 2009 ...
Breaking Medicine News(10 mins):Health News:Restore My Blood Sugar Review Reveals Exclusive Ways to Normalize Blood Sugar 2Health News:MedX Pharmacy Relocates to New Facility 2Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 2Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 3Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 4Health News:Resistance to key malaria drug spreading at alarming rate in Southeast Asia 2Health News:Tip-Over Furniture Can Kill Kids 2
... WASHINGTON and DUBLIN , March ... Ireland -based, physician-led global certification company, today announced that ... Mark on its new LuV300 vacuum with Kompressor® technology. ... range of products from worldwide manufacturers to determine their ...
... ... , ... ... On Thursday, March 18 , lawyers from the U.S. Department of Justice will appear in Federal District ...
... Care to Pay for It Makes Little Sense , ... ... PRINCETON, N.J. , March 16 Statement ... , , ...
... and suffering caused by antibiotic-resistant bacterial infections continue to rise ... (IDSA) is urging a global commitment to develop 10 new ... to address this public health crisis and safeguard patients, health. ... a statementpublished in the April 15 issue of Clinical ...
... has long been identified as a risk factor for cardiovascular ... researchers at the University of Rochester Medical Center found that ... risk of dying suddenly from cardiac causes. Scientists found ... underweight patients had a 76 percent increase in risk ...
... ... a new laundry detergent for U.S. consumers concerned about their budget as well as ... contains 10 ounces of macro-molecule laundry detergent which cleans for up to 12 months ... over 200 washes. , ...
Cached Medicine News:Health News:Ireland's Allergy Standards Limited Adds LG Electronics to Host of Companies Making Allergy-Certified Consumer Products 2Health News:Ireland's Allergy Standards Limited Adds LG Electronics to Host of Companies Making Allergy-Certified Consumer Products 3Health News:Ireland's Allergy Standards Limited Adds LG Electronics to Host of Companies Making Allergy-Certified Consumer Products 4Health News:Ireland's Allergy Standards Limited Adds LG Electronics to Host of Companies Making Allergy-Certified Consumer Products 5Health News:Court Hearing Thursday on Physicians' Challenge to 'Obamacare': Doctors Argue Against 'Arbitrary Power and Tyranny' 2Health News:Court Hearing Thursday on Physicians' Challenge to 'Obamacare': Doctors Argue Against 'Arbitrary Power and Tyranny' 3Health News:Court Hearing Thursday on Physicians' Challenge to 'Obamacare': Doctors Argue Against 'Arbitrary Power and Tyranny' 4Health News:NJHA: Charity Care Must Be a Priority as Uninsured Burden Grows 2Health News:ID physicians call for 10 new antibiotics by 2020 2Health News:As girth grows, risk of sudden cardiac death shrinks 2Health News:As girth grows, risk of sudden cardiac death shrinks 3Health News:Oransi Launches Robby Wash High Efficiency Laundry Detergent in U.S. – 10 Ounces Replaces 75 lbs. of Traditional Laundry Detergent 2Health News:Oransi Launches Robby Wash High Efficiency Laundry Detergent in U.S. – 10 Ounces Replaces 75 lbs. of Traditional Laundry Detergent 3
Ideal for chemical processing that requires downward flow of exhaust fumes. Powderful 1200 CFM blower draws fumes into sub-surface bonded charcoal filter for safe removal of organic vapors (final HEP...
... benchtop fume hood ventilates and ... indoor release of exhaust. Bonded ... contaminants. Configurations are available with ... include final HEPA filter, work ...
... proof polypropylene exhaust hoods are designed to ... and draw a stream of air across ... the operator. Other sizes and types of ... double-slot are available on special order in ...
... Benchtop Fume Hood is an economical unit ... which a number of fume hoods are ... colleges and universities. Features include a one-piece ... rounded inside corners for easy cleaning. A ...
Medicine Products: